ReviewChemical & biomedical imaging2026
Diagnostic Drugs: Concept, Current Status, and Challenges in New-Age Diagnosis Platform Development.
Review in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unmet medical needs form the basis for the discovery of diagnostic tools and drugs for diseases that elude existing treatment options. Herein, we provide a perspective on the current trends in diagnosis and treatment using conventional and state-of-the-art diagnostic drugs. Our report highlights the evolution of diagnosis and therapy, more so in the form of after pulmonary combining the drug discovery process with diagnostics known as "drug-diagnostic codevelopment", which has opened the doors for precision medicine. Modern-age diagnostic drugs, such as conjugating a drug to fluorophores via a covalent bond, have the potential to both detect and treat diseases. However, fluorescence quenching in solutions is a major bottleneck. This can be addressed using quantum dots (QDs) conjugated to drugs such as cadmium telluride (CdTe) QDs conjugated to 5-fluorouracil (5-FU), naproxen, and celecoxib. However, these conjugates could get aggregated, and they may also pose health risks due to the involvement of heavy metals. Supramolecular chemistry could play a pivotal role in addressing both the aggregation and safety issues without compromising its utility. The discovery of supramolecular aggregation-induced emission (AIE) probes and their applications to drug conjugates have been demonstrated in a few studies. Taken together, this report summarizes the significance of advanced diagnostic drugs possessing AIE-conjugated probes for use in diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.